AU2021223336B2 - Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereof - Google Patents

Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereof

Info

Publication number
AU2021223336B2
AU2021223336B2 AU2021223336A AU2021223336A AU2021223336B2 AU 2021223336 B2 AU2021223336 B2 AU 2021223336B2 AU 2021223336 A AU2021223336 A AU 2021223336A AU 2021223336 A AU2021223336 A AU 2021223336A AU 2021223336 B2 AU2021223336 B2 AU 2021223336B2
Authority
AU
Australia
Prior art keywords
prodrug
lipid
liposome
slnp
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021223336A
Other languages
English (en)
Other versions
AU2021223336A1 (en
Inventor
Dhruba Bharali
Bruce A. Hay
Tahmineh SAFAIE
David Stover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nammi Therapeutics Inc
Original Assignee
Nammi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nammi Therapeutics Inc filed Critical Nammi Therapeutics Inc
Publication of AU2021223336A1 publication Critical patent/AU2021223336A1/en
Application granted granted Critical
Publication of AU2021223336B2 publication Critical patent/AU2021223336B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021223336A 2020-02-19 2021-02-19 Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereof Active AU2021223336B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062995887P 2020-02-19 2020-02-19
US62/995,887 2020-02-19
PCT/US2021/010005 WO2021167703A1 (en) 2020-02-19 2021-02-19 Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof

Publications (2)

Publication Number Publication Date
AU2021223336A1 AU2021223336A1 (en) 2022-10-06
AU2021223336B2 true AU2021223336B2 (en) 2026-07-02

Family

ID=75223393

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021223336A Active AU2021223336B2 (en) 2020-02-19 2021-02-19 Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereof
AU2024339588A Pending AU2024339588A1 (en) 2020-02-19 2024-05-13 Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024339588A Pending AU2024339588A1 (en) 2020-02-19 2024-05-13 Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof

Country Status (8)

Country Link
US (3) US11801304B2 (cg-RX-API-DMAC7.html)
EP (2) EP4096716A1 (cg-RX-API-DMAC7.html)
JP (2) JP7842690B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220143063A (cg-RX-API-DMAC7.html)
CN (3) CN121287708A (cg-RX-API-DMAC7.html)
AU (2) AU2021223336B2 (cg-RX-API-DMAC7.html)
CA (1) CA3170142A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021167703A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7842690B2 (ja) * 2020-02-19 2026-04-08 ナミ セラピューティクス, インコーポレイテッド がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法
CN112669958B (zh) * 2020-12-08 2022-09-09 河北医科大学第二医院 代谢物作为疾病诊断的生物标志物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2409708A1 (en) * 2010-07-21 2012-01-25 B & G Partners, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2013082389A1 (en) * 2011-11-30 2013-06-06 Mallinckrodt Inc. Mmp-targeted therapeutic and/or diagnostic nanocarriers
WO2015166498A1 (en) * 2014-05-02 2015-11-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pt (iv) derivatives and nanocarriers comprising them
CN106176609A (zh) * 2016-08-22 2016-12-07 李因传 一种nk细胞膜仿生脂质体药物载体、制作方法及其应用
EP3276003A1 (en) * 2015-03-27 2018-01-31 Bonac Corporation Single-chain nucleic acid molecule having delivery function and gene expression control ability

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539748A1 (en) * 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
WO2006031471A2 (en) 2004-09-01 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Liposomal vectors
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
CA2632799A1 (en) 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
PT104158B (pt) 2008-08-18 2011-02-24 Univ Do Minho Aplicação da monooleína como novo lípido adjuvante em lipofecção
MX389666B (es) 2009-10-16 2025-03-19 Scripps Research Inst Induccion de celulas pluripotentes.
US20130189780A1 (en) 2009-12-31 2013-07-25 Fate Therapeutics, Inc. Reprogramming compositions
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
CN103857384B (zh) 2011-06-06 2017-07-11 大学健康网络 用于合成卟啉‑磷脂结合物的方法
CN104023749B (zh) 2011-09-14 2019-12-17 西北大学 能穿过血脑屏障的纳米缀合物
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
CA2874490C (en) * 2012-05-23 2021-11-16 The Ohio State University Tertiary quaternary amine-based cationic lipid nanoparticle compositions and methods of making and methods of using the same
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
AU2014278178B2 (en) 2013-06-11 2021-01-21 President And Fellows Of Harvard College SC-beta cells and compositions and methods for generating the same
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016149756A1 (en) * 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
WO2018081480A1 (en) * 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
IL268995B2 (en) 2017-03-02 2024-02-01 Nat Res Council Canada TGF-B receptor ectodomain fusion compounds and their uses
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
US11433143B2 (en) 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
CA3063932A1 (en) 2017-05-18 2018-11-12 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
US11046729B2 (en) 2017-10-26 2021-06-29 Southern Research Institute Dipeptide analogs as TGF-beta inhibitors
AU2018431586B2 (en) 2018-07-09 2025-03-20 Synthis Therapeutics, Inc Antibody-ALK5 inhibitor conjugates and their uses
US12448475B2 (en) * 2019-06-21 2025-10-21 The University Of North Carolina At Chapel Hill Drug delivery compositions and applications thereof
JP7842690B2 (ja) * 2020-02-19 2026-04-08 ナミ セラピューティクス, インコーポレイテッド がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2409708A1 (en) * 2010-07-21 2012-01-25 B & G Partners, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2013082389A1 (en) * 2011-11-30 2013-06-06 Mallinckrodt Inc. Mmp-targeted therapeutic and/or diagnostic nanocarriers
WO2015166498A1 (en) * 2014-05-02 2015-11-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pt (iv) derivatives and nanocarriers comprising them
EP3276003A1 (en) * 2015-03-27 2018-01-31 Bonac Corporation Single-chain nucleic acid molecule having delivery function and gene expression control ability
CN106176609A (zh) * 2016-08-22 2016-12-07 李因传 一种nk细胞膜仿生脂质体药物载体、制作方法及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURA SIMONA; BUI DUC TRUNG; COUVREUR PATRICK; NICOLAS JULIEN: "Lipid prodrug nanocarriers in cancer therapy", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, NL, vol. 208, 21 January 2015 (2015-01-21), NL, pages 25 - 41, XP029158890, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2015.01.021 *

Also Published As

Publication number Publication date
KR20260035240A (ko) 2026-03-12
CN115243724A (zh) 2022-10-25
EP4743119A1 (en) 2026-05-20
JP2026032152A (ja) 2026-02-25
AU2024339588A1 (en) 2026-02-26
US20240050575A1 (en) 2024-02-15
CN121287708A (zh) 2026-01-09
US20250032620A1 (en) 2025-01-30
CN121487753A (zh) 2026-02-06
CN115243724B (zh) 2025-10-21
AU2021223336A1 (en) 2022-10-06
CA3170142A1 (en) 2021-08-26
JP2023514324A (ja) 2023-04-05
JP7842690B2 (ja) 2026-04-08
EP4096716A1 (en) 2022-12-07
KR20220143063A (ko) 2022-10-24
US11801304B2 (en) 2023-10-31
WO2021167703A1 (en) 2021-08-26
US20210260197A1 (en) 2021-08-26